Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide

Zheng,Xiaojiao; Hua,Shixuan; Zhao,Hang; Gao,Zhou; Cen,Dong

doi:10.3892/ol.2022.13242

Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide

Authors:
- Xiaojiao Zheng
- Shixuan Hua
- Hang Zhao
- Zhou Gao
- Dong Cen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Ningbo First Hospital, Ningbo, Zhejiang 315035, P.R. China, Department of Laboratory Medicine, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang 315100, P.R. China
Published online on: February 15, 2022 https://doi.org/10.3892/ol.2022.13242
Article Number: 122

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to apoptosis induced by chemotherapy is still an obstacle for the treatment of chronic myeloid leukemia (CML). Numerous studies have indicated that upregulation of hepatocyte growth factor (HGF) protein expression reduced apoptosis induced by various factors. However, whether HGF has any effect on apoptosis induced by VP‑16 (etoposide) in CML cells and its underlying mechanisms are unclear. HGF was overexpressed in the K562 cell line using transfection. The protein and mRNA expression levels, and the concentration of HGF were measured using western blot analysis, reverse transcription‑quantitative (RT‑qPCR) and ELISA respectively. Apoptosis in the K562 cell line was determined using flow cytometry and western blot analysis. Changes in cell viability were measured using a MTT assay. RT‑qPCR and western blot analysis revealed that HGF was successfully upregulated at both the mRNA and protein expression levels in the K562 cell line, respectively. After VP‑16 treatment, the number of apoptotic cells overexpressing HGF was lower compared with that in cells transfected with the empty vector. Mechanistic investigation revealed that overexpression of HGF led to the increase in Bcl‑2 protein expression level and inhibition of caspase‑3/9 activation. Furthermore, HGF overexpression resulted in activation of the PI3K/Akt signaling pathway. Therefore, the results of the present study revealed that targeting HGF could be used as a strategy to overcome VP‑16 resistance in CML.

View Figures

View References

1	Quintás-Cardama A and Cortes J: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
2	Shimada A: Hematological malignancies and molecular targeting therapy. Eur J Pharmacol. 862:1726412019. View Article : Google Scholar : PubMed/NCBI
3	Holyoake TL and Vetrie D: The chronic myeloid leukemia stem cell: Stemming the tide of persistence. Blood. 129:1595–1606. 2017. View Article : Google Scholar : PubMed/NCBI
4	Jiang W, Hiscox S, Matsumoto K and Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 29:209–248. 1999. View Article : Google Scholar : PubMed/NCBI
5	Pons E, Uphoff CC and Drexler HG: Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leuk Res. 22:797–804. 1998. View Article : Google Scholar : PubMed/NCBI
6	Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS and Lee KB: Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 46:885–891. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls AF, Mayerhofer M and Valent P: Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: A novel mechanism of BCR-ABL1-independent disease progression. Neoplasia. 14:572–584. 2012. View Article : Google Scholar : PubMed/NCBI
8	Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW and Druker BJ: Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 121:396–409. 2011. View Article : Google Scholar : PubMed/NCBI
9	Crowley LC, Elzinga BM, O'Sullivan GC and McKenna SL: Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol. 86:38–47. 2011. View Article : Google Scholar : PubMed/NCBI
10	Liu MY, Wang WZ, Liao FF, Wu QQ, Lin XH, Chen YH, Cheng L, Jin XB and Zhu JY: Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro. Cell Biol Int. 41:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
11	Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng Y and Ma Q: Anti-tumor effects of Atractylenolide I on bladder cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Yu R, Yao J and Ren Y: A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567/PRDX3 axis in renal cell carcinoma. J Cell Mol Med. 24:10177–10188. 2020. View Article : Google Scholar : PubMed/NCBI
14	Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, Cho DJ, Kim DW and Lee JI: Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leuk Lymphoma. 57:1856–1864. 2016. View Article : Google Scholar : PubMed/NCBI
15	Mizui M, Isaka Y, Takabatake Y, Mizuno S, Nakamura T, Ito T, Imai E and Hori M: Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int. 65:2041–2053. 2004. View Article : Google Scholar : PubMed/NCBI
16	Suzuki A, Hayashida M, Kawano H, Sugimoto K, Nakano T and Shiraki K: Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology. 32:796–802. 2000. View Article : Google Scholar : PubMed/NCBI
17	Arakaki N, Kazi JA, Kazihara T, Ohnishi T and Daikuhara Y: Hepatocyte growth factor/scatter factor activates the apoptosis signaling pathway by increasing caspase-3 activity in sarcoma 180 cells. Biochem Biophys Res Commun. 245:211–215. 1998. View Article : Google Scholar : PubMed/NCBI
18	Schenk RL, Strasser A and Dewson G: BCL-2: Long and winding path from discovery to therapeutic target. Biochem Biophys Res Commun. 482:459–469. 2017. View Article : Google Scholar : PubMed/NCBI
19	Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, Karczewska E, Marlicz K, Stachura J and Hahn EG: Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther. 15:989–999. 2001. View Article : Google Scholar : PubMed/NCBI
20	Yalniz FF and Wierda WG: Targeting BCL2 in chronic lymphocytic leukemia and other hematologic malignancies. Drugs. 79:1287–1304. 2019. View Article : Google Scholar : PubMed/NCBI
21	Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA and Capitani S: Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 28:739–748. 2014. View Article : Google Scholar : PubMed/NCBI
22	Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A and Saki N: Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci. 72:2337–2347. 2015. View Article : Google Scholar : PubMed/NCBI
23	Chen JR, Jia XH, Wang H, Yi YJ, Wang JY and Li YJ: Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Int J Oncol. 48:2063–2070. 2016. View Article : Google Scholar : PubMed/NCBI
24	Ding X, Xi W, Ji J, Cai Q, Jiang J, Shi M, Yu Y, Zhu Z and Zhang J: HGF derived from cancerassociated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling. Oncol Rep. 40:1185–1195. 2018.PubMed/NCBI
25	Kuang W, Deng Q, Deng C, Li W, Shu S and Zhou M: Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2. Am J Transl Res. 9:3816–3826. 2017.PubMed/NCBI